PMID- 26558177
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20151111
LR  - 20240324
IS  - 2193-1801 (Print)
IS  - 2193-1801 (Electronic)
IS  - 2193-1801 (Linking)
VI  - 4
DP  - 2015
TI  - Patients' preferences and willingness-to-pay for postmenopausal hormone 
      receptor-positive, HER2-negative advanced breast cancer treatments after failure 
      of standard treatments.
PG  - 674
LID - 10.1186/s40064-015-1482-9 [doi]
LID - 674
AB  - Patients' preferences increasingly play roles in cancer treatments. The objective 
      of this study is to examine breast cancer patients' preferences and 
      willingness-to-pay (WTP) for postmenopausal hormone receptor-positive, 
      HER2-negative advanced breast cancer treatments after failure of standard 
      treatments. Four attributes, i.e. progression free survival (PFS), anemia, 
      pneumonitis, and cost, and their levels of exemestane and exemestane plus 
      everolimus from literature and patient interviews were used to develop a discrete 
      choice experiment questionnaire. Each questionnaire was composed of seven choice 
      sets and each choice set contained those four attributes with different levels. 
      Breast cancer patients were asked to choose one treatment alternative in each 
      choice set. Multinomial logit model was used to determine relative preferences of 
      each attribute and the WTP for all attributes and treatments were calculated. A 
      total of 146 patients were included in study analyses. Results showed that the 
      patients preferred treatments with higher PFS and lower side effects. The 
      patients were willing to pay US$151.6, US$69.8, and US$278.3 per month in 
      exchange for every 1 month increase in PFS and every 1 % decreased risk of anemia 
      and pneumonitis, respectively. The patients were willing to pay for exemestane 
      and exemestane plus everolimus US$551.8 and US$414.2 per month, respectively. In 
      conclusion, patients weighted importance on PFS, anemia, and pneumonitis, when 
      they needed to choose an aromatase inhibitor plus mammalian target of rapamycin 
      (mTOR) inhibitor for advanced breast cancer treatments after failure of standard 
      treatments. They valued exemestane alone more than exemestane plus everolimus.
FAU - Ngorsuraches, Surachat
AU  - Ngorsuraches S
AD  - Department of Pharmacy Practice, College of Pharmacy, South Dakota State 
      University, Brookings, SD, 57007 US.
FAU - Thongkeaw, Klangjai
AU  - Thongkeaw K
AD  - Maharaj Nakhon Si Thammarat Hospital, Nakhon Si Thammarat, 80000 Thailand.
LA  - eng
PT  - Journal Article
DEP - 20151105
PL  - Switzerland
TA  - Springerplus
JT  - SpringerPlus
JID - 101597967
PMC - PMC4635317
OTO - NOTNLM
OT  - Breast cancer
OT  - Everolimus
OT  - Exemestane
OT  - Patient preference
OT  - mTOR inhibitor
EDAT- 2015/11/12 06:00
MHDA- 2015/11/12 06:01
PMCR- 2015/11/05
CRDT- 2015/11/12 06:00
PHST- 2015/03/25 00:00 [received]
PHST- 2015/10/28 00:00 [accepted]
PHST- 2015/11/12 06:00 [entrez]
PHST- 2015/11/12 06:00 [pubmed]
PHST- 2015/11/12 06:01 [medline]
PHST- 2015/11/05 00:00 [pmc-release]
AID - 1482 [pii]
AID - 10.1186/s40064-015-1482-9 [doi]
PST - epublish
SO  - Springerplus. 2015 Nov 5;4:674. doi: 10.1186/s40064-015-1482-9. eCollection 2015.